Literature DB >> 30986704

Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib.

Chia-Yu Chen1, Chang-Fang Chiu2, Li-Yuan Bai3.   

Abstract

Entities:  

Year:  2019        PMID： 30986704     DOI： 10.1016/j.ejca.2019.03.016

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  1 in total

1.  Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept.

Authors:  Michelle Rosenzwajg; Joe-Elie Salem; Lee S Nguyen; Marie Bretagne; Jennifer Arrondeau; Noel Zahr; Stephane Ederhy; Baptiste Abbar; Bruno Pinna; Yves Allenbach; Jean-Paul Mira; Javid Moslehi
Journal:  J Immunother Cancer       Date:  2022-04       Impact factor: 13.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.